Imipenem reduces the efficacy of vancomycin against Elizabethkingia species

J Antimicrob Chemother. 2024 Aug 1;79(8):2048-2052. doi: 10.1093/jac/dkae210.

Abstract

Background: Elizabethkingia spp. are emerging as nosocomial pathogens causing various infections. These pathogens express resistance to a broad range of antibiotics, thus requiring antimicrobial combinations for coverage. However, possible antagonistic interactions between antibiotics have not been thoroughly explored. This study aimed to evaluate the effectiveness of antimicrobial combinations against Elizabethkingia infections, focusing on their impact on pathogenicity, including biofilm production and cell adhesion.

Methods: Double-disc diffusion, time-kill, and chequerboard assays were used for evaluating the combination effects of antibiotics against Elizabethkingia spp. We further examined the antagonistic effects of antibiotic combinations on biofilm formation and adherence to A549 human respiratory epithelial cells. Further validation of the antibiotic interactions and their implications was performed using ex vivo hamster precision-cut lung sections (PCLSs) to mimic in vivo conditions.

Results: Antagonistic effects were observed between cefoxitin, imipenem and amoxicillin/clavulanic acid in combination with vancomycin. The antagonism of imipenem toward vancomycin was specific to its effects on the genus Elizabethkingia. Imipenem further hampered the bactericidal effect of vancomycin and impaired its inhibition of biofilm formation and the adhesion of Elizabethkingia meningoseptica ATCC 13253 to human cells. In the ex vivo PCLS model, vancomycin exhibited dose-dependent bactericidal effects; however, the addition of imipenem also reduced the effect of vancomycin.

Conclusions: Imipenem reduced the bactericidal efficacy of vancomycin against Elizabethkingia spp. and compromised its capacity to inhibit biofilm formation, thereby enhancing bacterial adhesion. Clinicians should be aware of the potential issues with the use of these antibiotic combinations when treating Elizabethkingia infections.

MeSH terms

  • A549 Cells
  • Animals
  • Anti-Bacterial Agents* / pharmacology
  • Bacterial Adhesion / drug effects
  • Biofilms* / drug effects
  • Cricetinae
  • Drug Interactions
  • Flavobacteriaceae / drug effects
  • Flavobacteriaceae Infections* / drug therapy
  • Flavobacteriaceae Infections* / microbiology
  • Humans
  • Imipenem* / pharmacology
  • Lung / microbiology
  • Microbial Sensitivity Tests*
  • Vancomycin* / pharmacology

Substances

  • Imipenem
  • Anti-Bacterial Agents
  • Vancomycin